Evidence map›Paper›PMID 33172086›Full record

ArticleCancers2020

Cancer Alters the Metabolic Fingerprint of Extracellular Vesicles.

Mari Palviainen, Kirsi Laukkanen, Zeynep Tavukcuoglu, Vidya Velagapudi, Olli Kärkkäinen, Kati Hanhineva, Seppo Auriola, Annamari Ranki, Pia Siljander

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Metabolic features of tumor-derived extracellular vesicles: challenges and opportunities.Extracellular vesicles and circulating nucleic acids · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Mari PalviainenEV group, Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, 00790 Helsinki, Finland.ORCID 0000-0002-7105-3543
Kirsi LaukkanenDepartment of Dermatology and Allergology, Clinicum, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland.ORCID 0000-0001-6243-9850
Zeynep TavukcuogluEV group, Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, 00790 Helsinki, Finland.
Vidya VelagapudiMetabolomics Unit, Institute for Molecular Medicine Finland (FIMM), University of Helsinki, 00290 Helsinki, Finland.
Olli KärkkäinenLC-MS Metabolomics Center, School of Pharmacy, University of Eastern Finland, 70211 Kuopio, Finland.ORCID 0000-0003-0825-4956
Kati HanhinevaInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, 70211 Kuopio, Finland.
Seppo AuriolaLC-MS Metabolomics Center, School of Pharmacy, University of Eastern Finland, 70211 Kuopio, Finland.
Annamari RankiDepartment of Dermatology and Allergology, Clinicum, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland.
Pia SiljanderEV group, Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, 00790 Helsinki, Finland.
University of Helsinki · FIUniversity of Eastern Finland · FIUniversity of Turku · FI

Funding

Academy of Finland 287089Academy of Finland 315227
6 · The paper itself

Abstract

Cancer alters cell metabolism. How these changes are manifested in the metabolite cargo of cancer-derived extracellular vesicles (EVs) remains poorly understood. To explore these changes, EVs from prostate, cutaneous T-cell lymphoma (CTCL), colon cancer cell lines, and control EVs from their noncancerous counterparts were isolated by differential ultracentrifugation and analyzed by nanoparticle tracking analysis (NTA), electron microscopy (EM), Western blotting, and liquid chromatography-mass spectrometry (LC-MS). Although minor differences between the cancerous and non-cancerous cell-derived EVs were observed by NTA and Western blotting, the largest differences were detected in their metabolite cargo. Compared to EVs from noncancerous cells, cancer EVs contained elevated levels of soluble metabolites, e.g., amino acids and B vitamins. Two metabolites, proline and succinate, were elevated in the EV samples of all three cancer types. In addition, folate and creatinine were elevated in the EVs from prostate and CTCL cancer cell lines. In conclusion, we present the first evidence in vitro that the altered metabolism of different cancer cells is reflected in common metabolite changes in their EVs. These results warrant further studies on the significance and usability of this metabolic fingerprint in cancer.

Indexed as

cancer metabolismcolon cancercutaneous T-cell lymphomaextracellular vesiclesprostate cancer

Identifiers

PMID33172086
PMCPMC7694806
OpenAlexW3096116151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.